List of Key Companies Astrazeneca Sanofi Eli Lilly and Company Pfizer Inc
Browse all Peptides & GLP-1 education This independent editorial review carries no affiliate links and no sponsorship
doi: 10.7150/thno.67167 Summary Keywords polycystic ovary syndrome, gut microbiota, metabolic disorders, insulin resistance, bile acids Citation Li J, Qiao J, Li Y, Qin G, Xu Y, Lao K, Wang Y, Fan Y, Tang P and Han L (2025) Metabolic disorders in polycystic ovary syndrome: from gut microbiota biodiversity to clinical intervention
If you want specific sources to read, check the New England Journal of Medicine trial on GLP1 agents for metabolic outcomes, the 2024 JAMA Internal Medicine paper on semaglutide and mental health, the 2024 Scientific Reports analysis, and recent reviews by regulatory agencies and psychiatry meetings that discuss case reports and signal detection